home / stock / knbif / knbif news

KNBIF News and Press, Kane Biotech From 04/13/23

Stock Information
Company Name: Kane Biotech
Stock Symbol: KNBIF
Market: OTC
Website: kanebiotech.com
Menu
KNBIF KNBIF Quote KNBIF Short KNBIF News KNBIF Articles KNBIF Message Board
Get KNBIF Alerts

News, Short Squeeze, Breakout and More Instantly...
KNBIF - Kane Biotech to Release Fourth Quarter and Full Year 2022 Financial Results on April 20, 2023 - Conference Call to Follow

WINNIPEG, Manitoba, April 13, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove...
KNBIF - Kane Biotech Clarifies Terms of Credit Facility

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, March 03, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that, as previously announced by...

KNBIF - Kane Biotech Announces Amendment to its Credit Facility

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, March 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that it has entered into a ...

KNBIF - Kane Biotech Announces Proposed Amendments to its Credit Facility and Changes to its Board of Directors

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, March 01, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that Pivot Financial I Limi...
KNBIF - Kane Biotech’s Coactiv+™ Technology Could Address a Pricey and Painful Problem: Lack of Healing in Chronic Wounds Due to Microbial Biofilm Formation

(NewsDirect) By Richard Dal Monte Chronic wounds are a persistent and pricey problem for patients and health care systems around the world. Defined as “wounds that fail to proceed through the normal phases of wound healing in an orderly and timely manner,” chroni...

KNBIF - Kane Biotech's Coactiv+(TM) Technology Could Address a Pricey and Painful Problem: Lack of Healing in Chronic Wounds Due to Microbial Biofilm Formation

--News Direct-- By Richard Dal Monte Chronic wounds are a persistent and pricey problem for patients and health care systems around the world. Defined as “wounds that fail to proceed through the normal phases of wound healing in an orderly and timely manner,”...

KNBIF - Kane Biotech Announces Extension of Term of Credit Facility

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announces today that it has entered into an amending agre...
KNBIF - Kane Biotech Announces First Distribution Agreement for its coactiv+(TM) Antimicrobial Hydrogel

WINNIPEG, Manitoba, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has recently signed a distribution agreement with Salud Pharma S.A. (“Salud Pharma”) for its coactiv+...

KNBIF - Kane Biotech Announces Loan Transaction

WINNIPEG, Manitoba, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has reached an agreement to obtain loans (the “Loans”) in the aggregate amount of $2,000,000 from t...

KNBIF - Kane Biotech Announces Third Quarter 2022 Financial Results

WINNIPEG, Manitoba, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2022 financial results. Financial Highlights: Total revenue for the three months ...
Previous 10 Next 10